Clinical trial NCT01526174: Intratympanic Injection for Autoimmune Inner Ear Disease
Official title: Safety and Efficacy of Intratympanically Delivered Golimumab for Stabilization of Hearing in Patients With Autoimmune Inner Ear Disease: An Open-label Proof-of-concept Clinical Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Autoimmune Inner Ear Disease
Keywords: autoimmune
hearing loss
bilateral hearing loss
steroid-dependent
Lead sponsor: House Research Institute
Sponsor class: OTHER
Collaborators: name: Janssen Services, LLC
First posted: 2012-02-03
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators plan to conduct an open-label intratympanic injection proof-of-concept trial of golimumab, a TNF-alpha inhibitor, assessing for hearing loss progression in patients with autoimmune inner ear disease (AIED). This specific aim will be achieved using a two-arm approach. First, the investigators propose to dose 3 individual subjects with a single intratympanic injection of golimumab and follow each for 30 days, closely examining them for adverse events. If there are no serious adverse events, with FDA approval, the investigators propose to dose 14 subjects, each with 4 intratympanic injections of golimumab.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of autoimmune inner ear disease (AIED) by the principal investigator
* Idiopathic, bilateral sensorineural hearing loss
* History of, or audiograms showing, rapid progression of hearing loss
* Bilateral loss of at least 30 dB in one or more frequencies (0.25 - 6 kHz)
* Hearing responsive on high-dose oral steroids and steroid-dependent, as determined by history and the principal investigator. The subject can be taking oral steroid, at the maintenance level, if enrolled in the First Arm and, if enrolled in the Second Arm, will begin taper after the first injection.
* Provided written informed consent for participation in the clinical study

Exclusion Criteria:

* Positive MRI for vestibular schwannoma
* Positive FTA (syphilis)
* Significant middle ear disease (e.g., otitis media)
* Positive blood test for Lyme disease
* Positive tuberculosis test
* Concurrent or past treatment or use of medications and/or substances known to cause ototoxicity(for example, aminoglycosides \[e.g., gentamicin\], cisplatin, loop diuretics, Yorgason et al., 2006)
* Known adverse reaction to golimumab, adalimumab, etanercept, infliximab, rituximab, ustekinumab, or other biologic immunomodulators
* Concurrent (within the past 3 months prior to enrollment) live viral intranasal vaccine (flu)
* Positive test for HIV
* Positive test for Hepatitis B and C
* Presence of a demyelinating disease, such as multiple sclerosis
* Women of childbearing potential only: Positive serum pregnancy test prior to the only/first injection
* Active infections

Primary outcomes:
measure: Serious Adverse Events
timeFrame: 30 days
measure: Pure-tone threshold change
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: House Research Institute
name: Jennifer Derebery, MD
role: PRINCIPAL_INVESTIGATOR
References: